Background
Phase 2, open-label, 3-arm dose-optimization trial (OPTIC). N=283 patients with CP-CML who had ≥2 prior TKIs or the T315I mutation. All had received at least imatinib; T315I-mutant patients included regardless of prior lines. Designed to identify the optimal ponatinib starting dose and dose-reduction strategy to maximize efficacy while minimizing cardiovascular toxicity, directly addressing the arterial thrombotic event (ATE) signals from PACE. Published Blood 2021.
Interventions and follow up
Arm A: Ponatinib 45 mg PO daily, reduced to 15 mg on achieving BCR-ABL IS ≤1%
Arm B: Ponatinib 30 mg PO daily, reduced to 15 mg on achieving BCR-ABL IS ≤1%
Arm C: Ponatinib 15 mg PO daily continuously (no dose-reduction strategy)
Primary endpoint: BCR-ABL IS ≤1% at 12 months
Median follow-up: 32 months (primary); ~56 months (Leukemia 2024 update)
Arm B: Ponatinib 30 mg PO daily, reduced to 15 mg on achieving BCR-ABL IS ≤1%
Arm C: Ponatinib 15 mg PO daily continuously (no dose-reduction strategy)
Primary endpoint: BCR-ABL IS ≤1% at 12 months
Median follow-up: 32 months (primary); ~56 months (Leukemia 2024 update)
Results
BCR-ABL ≤1% at 12 months (Arm A): 44.7%
BCR-ABL ≤1% at 12 months (Arm B): 29.0%
BCR-ABL ≤1% at 12 months (Arm C): 23.1%
MMR at 24 months: Arm A 42.3%; Arm B 31.9%; Arm C 19.2%
T315I subgroup, BCR-ABL ≤1% at 12 months (Arm A): 52%
Arterial thrombotic events through 32 months: Arm A 9%, Arm B 5%, Arm C 3%, increasing with starting dose
BCR-ABL ≤1% at 12 months (Arm B): 29.0%
BCR-ABL ≤1% at 12 months (Arm C): 23.1%
MMR at 24 months: Arm A 42.3%; Arm B 31.9%; Arm C 19.2%
T315I subgroup, BCR-ABL ≤1% at 12 months (Arm A): 52%
Arterial thrombotic events through 32 months: Arm A 9%, Arm B 5%, Arm C 3%, increasing with starting dose
Adverse events
Vascular: ATE Arm A 9.2%, Arm B 4.8%, Arm C 2.9%; hypertension grade ≥3 12.7% (Arm A); atrial fibrillation and heart failure each <3% per arm; rates lower at all doses than continuous 45 mg in PACE (27% ATE at 5 yr)
Other: Pancreatitis grade ≥3 <5% all arms; dose reductions occurred rapidly (median 8–12 months) in responding Arm A patients, limiting ATE exposure time
Other: Pancreatitis grade ≥3 <5% all arms; dose reductions occurred rapidly (median 8–12 months) in responding Arm A patients, limiting ATE exposure time
Conclusions
OPTIC established that a 45 mg starting dose with reduction to 15 mg on achieving BCR-ABL ≤1% provides the best balance of efficacy (44.7% ≤1% rate at 12 months) and tolerability, with ATE rates substantially lower than the continuous 45 mg used in PACE. This dose-reduction strategy is now the recommended approach for ponatinib in TKI-resistant CML.
Key Limitations
Non-randomized open-label 3-arm design without a comparator; cross-arm comparisons are not powered for superiority. ATE rates, while lower than PACE, remain 9% in Arm A at 3 years, requiring careful benefit-risk assessment in patients with cardiovascular risk factors. The efficacy endpoint (BCR-ABL ≤1% at 12 months) is a surrogate; PFS and OS not formally compared across arms. The dose-reduction trigger is pragmatic but not validated as optimal. Arm C had lowest toxicity but also lowest response, suggesting 15 mg frontloading is insufficient for most resistant patients.
Clinical Context
OPTIC led to an FDA label update for ponatinib in March 2022 recommending the 45→15 mg dose-reduction strategy for CML; this is now the standard dosing. For T315I-mutant patients, both ponatinib (OPTIC/PACE) and asciminib 200 mg BID (ASCEMBL T315I cohort) are active. Olverembatinib is a third option post-ponatinib or post-asciminib failure. Per ELN recommendations, ponatinib with dose reduction is a preferred option for T315I and resistant CML. ESMO-MCBS: not assigned.